TerminatedPhase 2NCT03919162

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vivoryon Therapeutics N.V.
Principal Investigator
Howard Feldman
Alzheimer's Disease Cooperative Study (ADCS)
Intervention
PQ912(drug)
Enrollment
112 enrolled
Eligibility
50-89 years · All sexes
Timeline
20212024

Study locations (22)

Collaborators

Alzheimer's Disease Cooperative Study (ADCS) · National Institute on Aging (NIA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03919162 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials